EP 4304711 A1 20240117 - GLP-1R MODULATING COMPOUNDS
Title (en)
GLP-1R MODULATING COMPOUNDS
Title (de)
VERBINDUNGEN ZUR GLP-1R-MODULATION
Title (fr)
COMPOSÉS MODULATEURS DE GLP-1R
Publication
Application
Priority
- US 202163159853 P 20210311
- US 2022019593 W 20220309
Abstract (en)
[origin: WO2022192428A1] The present disclosure provides GLP-1R agonists of Formula (I), and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
IPC 8 full level
A61P 1/00 (2006.01); A61K 31/4184 (2006.01); A61P 5/00 (2006.01); A61P 9/00 (2006.01); A61P 19/00 (2006.01); A61P 25/00 (2006.01); C07D 401/14 (2006.01); C07D 409/14 (2006.01); C07D 417/14 (2006.01)
CPC (source: EP US)
A61K 31/4545 (2013.01 - US); A61K 45/06 (2013.01 - US); A61P 1/00 (2018.01 - EP); A61P 1/16 (2018.01 - US); A61P 5/00 (2018.01 - EP); A61P 9/00 (2018.01 - EP); A61P 19/00 (2018.01 - EP); A61P 25/00 (2018.01 - EP); C07D 401/14 (2013.01 - EP); C07D 405/14 (2013.01 - US); C07D 409/14 (2013.01 - EP US); C07D 417/14 (2013.01 - EP US); C07D 211/14 (2013.01 - US)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
WO 2022192428 A1 20220915; EP 4304711 A1 20240117; TW 202241876 A 20221101; TW I819518 B 20231021; US 12091404 B2 20240917; US 2022298148 A1 20220922
DOCDB simple family (application)
US 2022019593 W 20220309; EP 22713183 A 20220309; TW 111108691 A 20220310; US 202217690889 A 20220309